The rheumatology/dermatology collaboration.
Psoriatic arthritis (PsA) of often has a destructive course, characterized by progressive damage to bone and joints. Consequently, prompt detection is critical, allowing effective, disease-modifying treatment to be administered at the earliest possible point in the progression of the disease. The collaboration between dermatologic and rheumatologic professionals in the early diagnosis, and subsequent management, of PsA is explored, with a focus on case studies that illustrate the potentialfor such collaboration.
Young
Melodie S
MS
Modern Dermatology, Dallas, TX, USA.
Furfaro
Nicole
N
D000328:Adult; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000628:therapy; D003299:Cooperative Behavior; D003663:Decision Trees; D003880:Dermatology / Q000458:organization & administration*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008403:Mass Screening / Q000379:methods; D008487:Medical History Taking; D008875:Middle Aged; D009722:Nurse Practitioners / Q000458:organization & administration; D009730:Nursing Assessment; D010348:Patient Care Team / Q000458:organization & administration*; D010353:Patient Education as Topic / Q000458:organization & administration; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012017:Referral and Consultation / Q000458:organization & administration; D012219:Rheumatology / Q000458:organization & administration*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept